Introduction {#S1}
============

The human gut represents the largest mucosal surface area and is the largest immune organ of the body ([@B1]). Full-term infants are born with a competent but immature immune system that must respond appropriately to the inevitable exposure to microbes that occurs following birth. The infant microbiota is derived principally from the maternal microbiota ([@B2]) and the early colonizers of the gut play a critical role in priming mucosal immunity and establishing a homeostatic relationship with the host ([@B3], [@B4]).

*Enterococcus faecalis* is one of the most abundant colonizers of the infant gastrointestinal tract ([@B5], [@B6]) and together with other enterococci, staphylococci, and enterobacteria helps reduce the gut environment to facilitate subsequent colonization by obligate anaerobes ([@B7], [@B8]). Select *E. faecalis* infant derived strains also possess immunomodulatory capacities ([@B9]) and exert anti-inflammatory activities by modulating the nuclear factor kappa B (NF-κB), mitogen-activated protein kinase and peroxisome proliferator-activated receptor-γ1 regulated pathways ([@B10], [@B11]). Some of the immunomodulatory factors produced by *E. faecalis* have been identified ([@B12]--[@B14]); however, the extent of immunomodulatory capacities among non-pathogenic gut strains, and the identity of the bioactives that underpin them, remains largely unknown.

Taken together, we hypothesized the infant gut microbiota would be a fertile source of immunomodulatory bioactive factors with potential prophylactic or therapeutic applications. We previously reported a method termed metaparental mating (MPM) that enables the rapid and directed isolation of genetically tractable human gut bacteria ([@B15]). In this study, we describe the isolation of *E. faecalis* AHG0090 and demonstrate that similar to *Faecalibacterium prausnitzii* A2-165 ([@B16], [@B17]), it produces a potent peptidic bioactive that suppresses NF-κB activation. Finally, we demonstrate that *E. faecalis* AHG0090 can be manipulated using traditional molecular techniques providing new opportunities to dissect the functional capacity of the human gut microbiota.

Materials and Methods {#S2}
=====================

Growth and Culture Conditions {#S2-1}
-----------------------------

The recipient cultures for MPM were prepared by inoculating Brain Heart Infusion (BHI, Difco™) supplemented with colistin sulfate with a raw stool sample collected from a healthy 2-year-old female child. The donor had not taken antibiotics during the 3-month period prior to collection. The child was recruited as part of a study into the link between the gut microbiota and type 1 diabetes susceptibility. All study samples were collected in accordance with the recommendations of the Mater Health Services Human Research Ethics Committee (HREC/13/MHS/21/AM02). All subjects gave written informed consent in accordance with the Declaration of Helsinki, with written consent provided from parents or legal guardians for all subjects \<13 years. The protocol was approved by the Mater Health Services HREC. *E. faecalis* was cultured in BHI and the *Escherichia coli* ST18 donor strain for MPM was cultured in BHI supplemented with δ-aminolevulinic acid (100 µg ml^−1^). The *E. coli* cloning strains were grown in LB and *F. prausnitzii* A2-165 was cultured in anaerobic Reinforced Clostridial Medium (RCM, Oxoid™) buffered with salt solutions 2 and 3 ([@B18]). *F. prausnitzii* cultures were routinely manipulated in a Coy vinyl anaerobic chamber with an oxygen free atmosphere (85% N~2~:10% CO~2~:5% H~2~). Both *E. coli* ST18 and JM109 competent cells were prepared by the rubidium chloride method ([@B19]) while Invitrogen™ *E. coli* DH5 α competent cells were purchased from ThermoFisher Scientific. The bacterial growth media were supplemented with erythromycin (100 µg ml^−1^), chloramphenicol (20 µg ml^−1^) or colisitin sulfate (20 µg ml^−1^) as appropriate.

Bacterial growth was measured by the increase in optical density at 600 nm (OD~600 nm~). Specific growth rates \[μ (h^−1^)\] were calculated by log~10~ transformation of the OD~600 nm~ measurements and plotting a trendline (R^2^ \> 0.97) for the linear phase of growth corresponding to exponential (EX) growth phase. Then μ was calculated using the equation: μ = (slope of the line × 2.3).

Vector Construction and Manipulation {#S2-2}
------------------------------------

To construct pEHR513111, *catP* was PCR amplified from pJIR1456 ([@B20]) with primers (P~f~ 5′ GAT CGT TTA AAC AGT GGG CAA GTT GAA AAA TTC AC; P~r~ 5′ GAT CCC TGC AGG TTA GGG TAA CAA AAA ACA CCG TAT TTC TAC) that introduced unique PmeI and SbfI restriction sites. The digested *catP* was then cloned into pEHR512111, replacing *erm*, and generating pEHR513111. The pEHR513112 vector was subsequently constructed by cloning *cphy_3290-evolglow-C-Bs2* from pEHR512112 ([@B15]) into the multiple cloning site of pEHR513111 as an EcoRI-HindIII fragment. The pEHR513111 and pEHR513112 vectors were confirmed by restriction digest analysis and the sequences compiled using publicly available sequences. When appropriate, the pEHR513112 vector was cured from *E. faecalis* AHG0090 by overnight growth in BHI medium supplemented with acridine orange (1--8 µg ml^−1^) and then plating on BHI medium. Single colonies were replica plated onto BHI medium with or without chloramphenicol to identify naïve *E. faecalis* AHG0090 isolates.

Plasmid DNA was extracted from *E. faecalis* cultures using a modified alkaline lysis method ([@B21]). Briefly, 1 ml of *E. faecalis* culture was centrifuged and the cells were resuspended in 200 µl of solution 1. The cell suspension was supplemented with 1 µl of mutanolysin (20 U/μl) and 10 µl lysozyme (200 mg ml^−1^) and incubated at 37°C for up to 1 h. Next, 200 µl of solution 2 was added, and the mixture was incubated on ice for 5 min. Then, 200 µl of solution 3 was added, and the mixture was incubated on ice for 10 min. The cell debris were removed by centrifugation and the clarified cell lysate was recovered and extracted with phenol:chloroform:isoamyalcohol (25:24:1). The aqueous phase was transferred to a fresh tube and plasmid DNA was precipitated using isopropanol, washed with 70% (v/v) ethanol and then resuspended in TE buffer. Plasmid DNA was similarly prepared from *E. coli* except that the treatments with mutanolysin and lysozyme, and the incubations on ice were not performed.

Mating Procedures {#S2-3}
-----------------

The *E. coli* ST18 donor strain for metaparental and biparental matings was grown in BHI medium supplemented with δ-aminolevulinic acid and chloramphenicol. The MPM experiments were performed essentially as previously described ([@B15]) with two exceptions. First, the mating mix and controls were spotted directly onto the surface of BHI agar rather than plating on a nylon filter. Second, 100 µl of mating mix and controls were transferred to fresh BHI broth and grown for 5 h before selecting for transconjugants. Biparental matings were similarly performed except that the 5 h outgrowth was not done. Transconjugants were recovered on BHI medium supplemented with chloramphenicol and colisin sulfate.

Microscopy {#S2-4}
----------

Naïve and transconjugants strains of *E. faecalis* AHG0090 were examined with an Olympus BX 63 microscope fitted with an Xcite LED light source and fluorescence filter cube U-FBN (excitation 470--495 nm, emission 510 nm). Images were captured using a DP80 camera and the Olympus cellSens modular imaging software platform and ImageJ software package[^1^](#fn1){ref-type="fn"} were used for visualization and processing.

*E. faecalis rrs* Sequencing {#S2-5}
----------------------------

The *rrs* gene was PCR amplified using the primers 27F and 1492R ([@B22]) as previously described ([@B23]), and sequenced at the Australian Genomic Research Facility (Brisbane, Australia) using primers 530F and 907R ([@B22]). The individual sequence reads were trimmed to remove low quality bases and assembled using deFUME ([@B24]). The assembled sequence was then aligned against the Ribosomal Database Project ([@B25]) core set of aligned *rrs* sequences and *E. faecalis* AHG0090 was identified using the Classifier and SeqMatch functions.

Genome Sequencing and Analysis {#S2-6}
------------------------------

High molecular weight DNA was prepared from the *E. faecalis* AHG0090 MPM isolate as previously described ([@B23]). The DNA was then quantified using the QuantiFluor ONE dsDNA system according to manufacturer's instructions (Promega, Australia) and the integrity of the DNA was determined by agarose gel electrophoresis. The genome was shotgun sequenced using the Illumina NextSeq 500 system (2 × 150bp High Output kit) with v2 chemistry. The sequence data were quality checked, filtered, and then *de novo* assembled using the SPAdes assembler v 3.10.1 ([@B26]). Genome sequencing quality was evaluated with CheckM, which estimates the input files for completeness and contamination based on the phylogenetic assignment of a broad set of marker genes ([@B27]). The *E. faecalis* AHG0090 contigs were ordered using Mauve ([@B28]) with the closed *E. faecalis* V583 genome sequence used as a reference. The Mauve generated assembly was submitted to the RAST annotation pipeline and the results were examined in the SEED Viewer ([@B29]). Genome based phylogeny was obtained using GTDB,[^2^](#fn2){ref-type="fn"} built from the concatenation of 120 universal bacterial-specific marker genes ([@B30]). Tree inference was performed with FastTree v2.1.7 ([@B31]) and included all genomes in IMG v4.510 ([@B32]). The resulting tree was imaged using ARB v6.0.6 ([@B33]). To identify candidate plasmids, the fastq files were mapped to the *E. faecalis* AHG0090 genome assembly using BamM v1.7.3[^3^](#fn3){ref-type="fn"} to determine the coverage profiles for each contig. The average coverage was then calculated and contigs with \>1,000× coverage were identified as candidate plasmids. In addition, we used PlasmidSPAdes to assemble plasmids from whole genome sequencing data ([@B34]). The candidate plasmids were manually curated to determine if they could be closed and compared to other plasmids using Blastn. This Whole Genome Shotgun project was deposited at DDBJ/EMBL/GenBank under the accession PDUN00000000. The version described in this paper is the first version, PDUN01000000.

Measurement of *E. faecalis* Immunomodulatory Activities {#S2-7}
--------------------------------------------------------

The immunomodulatory potential of *E. faecalis* was assessed using LS174T-NF-κB*luc* goblet cell like and Caco-2-NF-κB*luc* enterocyte-like reporter cell lines ([@B35]). Briefly, three individual *E. faecalis* AHG0090 colonies were established as independent cultures with BHI broth. Following overnight growth, each individual culture was used to initiate duplicate 50 ml BHI broth cultures at a starting OD~600 nm~ of 0.01 (*n* = 6 cultures, consisting of *n* = 3 independent biological replicates with *n* = 2 technical replicates each). The OD~600 nm~ of the cultures was monitored longitudinally and 5 ml of cultures was harvested from each broth culture at early EX, mid-exponential (MX), early stationary (ES), and late stationary (LS) phase of growth. At each collection, 1.5 ml of each culture was centrifuged at 16,000 × *g* for 5 min and 0.5 ml of the cell-free supernatant fraction was transferred to fresh tubes and stored at −30°C as single-use aliquots.

For the immunomodulatory assays, 96-well microtiter plates were seeded with 20,000 LS174T-NF-kB*luc* or Caco-2-NF-kB*luc* reporter cells per well as previously described ([@B35]). The ability of the cell-free bacterial supernatants to suppress NF-κB activation in LS174T-NF-kB*luc* was assessed by adding supernatant (10% v/v in complete DMEM medium) to the cells and incubating for 30 min at 37°C. The LS174T and Caco-2 reporter cell lines were then stimulated with TNFα (25 ng ml^−1^) or IL-1β (50 ng ml^−1^), respectively, in the presence of 10% v/v supernatant for 4 h before assessing luciferase activity. The ability of the supernatants to suppress activation was compared to the NF-κB inhibitor indole-3-carbinol (I3C, 5 µM). NF-κB driven luciferase expression was assessed using the Pierce™ Firefly Luc One-Step Glow Assay Kit (ThermoFisher Scientific) according to the manufacturer's instructions. The cytotoxicity of the supernatants was assessed using Cell Proliferation Reagent WST-1 (Sigma Aldrich) according to the manufacturer's instructions.

Nuclear Translocation Immunofluorescence Assays {#S2-8}
-----------------------------------------------

Glass coverslips in a 12 well-plate were seeded with 20,000 Caco-2 cells per well and cultured overnight. Cell-free culture supernatants harvested from MX phase cultures were added (10% v/v) to the Caco-2 cells and incubated for 30 min and then stimulated with IL-1β (25 ng ml^−1^) for 1 h. Cells were also treated with BHI medium and I3C alone. The cells were then processed and analyzed as previously described ([@B35]).

Quantitative Reverse Transcriptase PCR (qRT-PCR) Assays {#S2-9}
-------------------------------------------------------

A 12-well plate was seeded with 50,000 Caco-2 cells per well and cultured overnight. Cell-free culture supernatants harvested from MX phase cultures were added (10% v/v) to the Caco-2 cells and incubated for 30 min and then stimulated with IL-1β (25 ng ml^−1^) for 6 h. Cells were also treated with I3C and BHI medium alone. Total RNA was isolated and the expression of the NF-κB-dependent genes IL-6, IL-8 and CXCL10 was assessed as previously described ([@B35]), except that different primers were used for IL-6 (P~f~ 5′ CCA CTC ACC TCT TCA GAA CG; P~r~ 5′ CAT CTT TGG AAG GTT CAG GTT G) ([@B36]).

Results {#S3}
=======

Isolation of *E. faecalis* AHG0090 {#S3-1}
----------------------------------

To recover genetically tractable facultative anaerobic *Firmicutes* bacteria from the healthy infant human gut, we produced a microbial enrichment culture from human stool and determined that chloramphenicol completely inhibited growth of candidate recipients on BHI medium under aerobic conditions. Consequently, we constructed a vector, pEHR513111, carrying *catP*, and this vector was further modified by cloning the *evoglow-C-Bs2* under the control of the *Clostridium phyofermentans* ISDg *cphy_3290* promoter generating pEHR513112 (Figure [1](#F1){ref-type="fig"}A).

![**(A)** The pEHR513111 plasmid carrying *catP* confers chloramphenicol resistance on its host. The pEHR513112 plasmid carries *evoglow-C-Bs2* under the control of the *Clostridium phyofermentans* ISDg *cphy_3290* promoter. **(B)** Plasmid profiling of the transconjugants recovered by metaparental mating (MPM isolates). The pEHR513112 plasmid carried by the transconjugants was identified by comparison with plasmid DNA prepared from *Escherichia coli* (pEHR513112).](fimmu-09-00790-g001){#F1}

Following MPM, we recovered 14 transconjugants and assessed the clonality of 12 isolates by plasmid profiling. All 12 isolates carried a plasmid of comparable molecular weight to pEHR513112 in addition to at least two other plasmids (\~1.4 kb closed covalent circular form, \~3.2 kb closed covalent circular form) (Figure [1](#F1){ref-type="fig"}B). However, the plasmid DNA profiles of all 12 isolates were virtually identical suggesting they were clonal. Based on these observations, we chose one transconjugant for further analysis and produced 1,473 bp of 16S rRNA sequence. Based on this sequence, we determined the isolate was affiliated with the *E. faecalis* taxon, and hereafter it is referred to as *E. faecalis* AHG0090.

*E. faecalis* AHG0090 is Genetically Tractable {#S3-2}
----------------------------------------------

We examined whether *E. faecalis* AHG0090 can be genetically manipulated using traditional techniques in molecular microbiology. *E. faecalis* AHG0090 was grown in BHI broth supplemented with acridine orange to cure pEHR513112. The addition of acridine orange up to 8 µg ml^−1^ did not affect growth; however, all the colonies recovered on BHI medium were sensitive to chloramphenicol suggesting they had lost pEHR513112. Plasmid DNA prepared from *E. faecalis* AHG0090 recovered by MPM carried a plasmid with the same molecular weight as pEHR513112, however, this plasmid was absent from naïve *E. faecalis* AHG0090 (Figure [2](#F2){ref-type="fig"}A). We next confirmed that naïve *E. faecalis* AHG0090 was genetically tractable by using it as the recipient in a biparental mating with *E. coli* ST18 carrying pEHR513112. Using our standard biparental mating protocol, we recovered transconjugants and achieved a conjugation efficiency of 3.83 × 10^−7^ transconjugants per recipient. As expected, the biparental mating-derived transconjugant carried the pEHR513112 plasmid band (Figure [2](#F2){ref-type="fig"}A) and plasmid recovery experiments from the MPM and re-transformed isolates confirmed the plasmids were stably maintained (Figure [2](#F2){ref-type="fig"}B). Consistent with these observations the re-transformed but not naïve strain was fluorescent (Figure [2](#F2){ref-type="fig"}C). Notably, the endogenous plasmids were unaffected by the acridine orange treatment suggesting that they are stably maintained.

![**(A)** *Enterococcus faecalis* AHG0090 is genetically tractable and can be manipulated using standard molecular microbiology approaches. The pEHR513112 plasmid was readily identifiable in *E. faecalis* AHG0090 recovered by metaparental mating (original MPM isolate) and following the re-introduction of the plasmid by biparental mating (re-transformed), but was lost following treatment with acridine orange (naïve strain). The absence of pEHR513112 in the naïve strain is indicated by a red arrow. **(B)** The pEHR513112 plasmid is stably maintained in *E. faecalis* AHG0090. pEHR513112 plasmids recovered from *E. faecalis* AHG0090 transconjugants produced by MPM and following re-transformation of the naïve strain were examined by agarose gel electrophoresis to identify any major structural deletions and re-arrangements. **(C)** *E. faecalis* strains carrying pEHR513112 are fluorescent. *Escherichia coli* ST18 carrying pEHR513112 and naïve and transconjugant *E. faecalis* AHG0090 strains were analyzed using brightfield and fluorescence microscopy. The scale bars represent 10 µm.](fimmu-09-00790-g002){#F2}

*E. faecalis* AHG0090 Produces an NF-κB Suppressive Peptidic Bioactive {#S3-3}
----------------------------------------------------------------------

Given the immunomodulatory activity previously ascribed to *E. faecalis* isolates, we examined the ability of *E. faecalis* AHG0090 to suppress cytokine-mediated epithelial NF-κB activation using our LS174T and Caco-2 reporter cell lines. *E. faecalis* AHG0090 was grown in BHI medium and achieved a specific growth rate of 1.63 ± 0.14 h^−1^ (growth rate ± SD) during EX growth phase and a maximum recorded yield of 3.74 ± 0.07 (OD~600~ ± SD) following 8 h of growth (Figure [3](#F3){ref-type="fig"}A). Cell-free supernatants were harvested from early EX, MX, ES and LS phase cultures as the closely related bacterium *Lactobacillus plantarum* produces immunomodulins that inhibit IFNγ production in a growth phase dependent manner ([@B37]). Culture supernatant harvested from all four-time points suppressed NF-κB activation in both cell lines although the extent of suppression was greatest with supernatants harvested from MX phase onward (Figure [3](#F3){ref-type="fig"}B).

![**(A)** Harvesting of *Enterococcus faecalis* AHG0090 cell-free culture supernatants. *E. faecalis* AHG0090 was cultured in Brain Heart Infusion (BHI) medium and culture supernatants were harvested in early exponential (EX), mid-exponential (MX), early stationary (ES) and late stationary (LS) phase. Growth was recorded as the change in optical density over time (hours). **(B)** Characterization of the nuclear factor kappa B (NF-κB) suppressive capacity of *E. faecalis* AHG0090. The effects of the *E. faecalis* AHG0090 culture supernatants on NF-κB activation in the LS174T-NF-κB*luc* and Caco-2-NF-κB*luc* reporter cell lines were measured by the luciferase assay. The extent of NF-κB activation was assessed after 6 h stimulation with TNFα/IL-1β and baseline suppression of the reporter gene was assessed using sterile BHI medium (\*\**p* \< 0.01, \*\*\**p* \< 0.001 as determined by one-way ANOVA with Dunnett's multiple comparison test).](fimmu-09-00790-g003){#F3}

We compared the NF-κB suppressive capacity of *E. faecalis* AHG0090 to the model anti-inflammatory gut bacterium *F. prausnitzii* A2-165 and determined that both strains suppressed NF-κB activation to a similar extent in the LS174T and Caco-2 reporter cell lines (Figure [4](#F4){ref-type="fig"}A). Critically, the *E. faecalis* AHG0090 and *F. prausnitzii* A2-165 cell-free supernatants did not exert cytotoxic effects. The *E. faecalis* AHG0090 culture supernatant was fractionated by passing it through a 3 kDa molecular weight cut-off filter and the NF-κB suppressive activity of the flow-through but not the retentate was similar to that of the unfractionated culture supernatant (Figure [4](#F4){ref-type="fig"}A). We next assessed the impact of heat and proteinase K treatments on the *F. prausnitzii* A2-165 and *E. faecalis* AHG0090 NF-κB suppressive bioactives. The activity of the *F. prausnitzii* A2-165 \<3 kDa culture supernatant fraction was not significantly different to the Reinforced Clostridial Medium control following heat (57 and 97°C) or proteinase K treatment (Figure [4](#F4){ref-type="fig"}B), consistent with the NF-κB suppressive capacity of this bacterium being mediated by Mam-derived peptides ([@B16]). The *E. faecalis* AHG0090 \<3 kDa culture supernatant fraction displayed similar characteristics but still retained activity following treatment at 57°C for 30 min or proteinase K digestion for 1 h when compared to the BHI control (Figure [4](#F4){ref-type="fig"}B, *p* \< 0.05). This activity was lost at higher temperatures or following longer heat treatment and following extended proteinase K treatment (Figure [4](#F4){ref-type="fig"}B). Taken together, these data suggest *E. faecalis* AHG0090 secretes a low molecular weight NF-κB suppressive peptidic bioactive with differing properties to the *F. prausnitzii* Mam peptides.

![**(A)** *Faecalibacterium prausnitzii* A2-165 and *Enterococcus faecalis* AHG0090 produce low molecular weight nuclear factors kappa B (NF-κB) suppressive bioactives. The extent of NF-κB activation was assessed after 6 h stimulation of the LS174T-NF-kB*luc* and Caco-2-NF-kB*luc* reporter cell lines with TNFα and IL-1β, respectively. Baseline suppression of the reporter gene was assessed using sterile Reinforced Clostridial Medium (RCM) or Brain Heart Infusion (BHI) medium. The suppressive effects of the supernatants were assessed against the appropriate medium control. **(B)** *F. prausnitzii* A2-165 and *E. faecalis* AHG0090 produce heat and proteinase K labile bioactives. The effect of the heat and proteinase K treatments was assessed using the LS174T-NF-κB*luc* reporter cell line. The suppressive effects of the supernatants were assessed against the appropriate medium control and significant differences are indicated. ns, not significant, \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001 as determined by one-way ANOVA with Dunnett's multiple comparison test.](fimmu-09-00790-g004){#F4}

*Enterococcus faecalis* AHG0090 Inhibits NF-κB-p65 Subunit Nuclear Translocation and Cytokine Expression {#S3-4}
--------------------------------------------------------------------------------------------------------

Cytokine mediate activation of the NF-κB pathway results in nuclear translocation of the NF-κB-p65 subunit. We examined the ability of culture supernatant harvested from MX phase cultures of *E. faecalis* AHG0090 to suppress NF-κB-p65 subunit nuclear translocation. NF-κB-p65 subunit nuclear translocation induced by IL-1β in Caco-2 cells was unaffected by treatment with BHI medium. In contrast, *E. faecalis* AHG0090 MX phase culture supernatant treatment significantly reduced nuclear translocation in a similar fashion to the pharmacological inhibitor I3C (Figure [5](#F5){ref-type="fig"}A). As expected, I3C and *E. faecalis* AHG0090 culture supernatant suppressed expression of the NF-κB-dependent genes IL-6 (*p* \< 0.05), IL-8 (*p* \< 0.01) and CXCL10 (*p* \< 0.001), as determined by qRT-PCR (Figure [5](#F5){ref-type="fig"}B).

![**(A)** *Enterococcus faecalis* AHG0090 mid-exponential (MX) phase culture supernatant suppresses nuclear factor kappa B (NF-κB)-p65 subunit nuclear translocation. The cell nuclei and NF-κB-p65 subunit are shown in blue and green, respectively. The nuclei for the Brain Heart Infusion (BHI) treated Caco-2 cells in the central panel are largely black revealing that treatment does not result in nuclear translocation. As expected, BHI treatment does not prevent NF-κB-p65 nuclear translocation following IL-1β treatment as indicated by green staining of the nuclei. By contrast, treatment with I3C and *E. faecalis* AHG0090 MX phase culture supernatant suppressed IL-1β-induced NF-κB-p65 nuclear translocation. The scale bars represent 10 µm. **(B)** *E. faecalis* AHG0090 MX phase culture supernatants suppress expression of NF-κB-p65-dependent cytokines. The expression of IL-6, IL-8 and CXCL10 was assessed by quantitative reverse transcriptase PCR. The data are normalized to GAPDH gene expression and presented as the fold-change relative to unstimulated cells. *E. faecalis* AHG0090 MX phase culture supernatants suppress expression of IL-6 (\**p* \< 0.05), IL-8 (\*\**p* \< 0.01) and CXCL10 (\*\*\*\**p* \< 0.0001) as determined using one-way ANOVA with Dunnett's multiple comparison test.](fimmu-09-00790-g005){#F5}

*E. faecalis* AHG0090 Is Adapted for Gut Colonization {#S3-5}
-----------------------------------------------------

We sequenced the *E. faecalis* AHG0090 genome to provide insights into the factors supporting colonization and persistence in the infant gut. We produced 2,925,542 bp of DNA sequence at 107× coverage. The sequenced data were assembled into 116 contigs providing a contig N~50~ of 144,336 bp and L~50~ of 8. Critically, the genome was assessed by CheckM as being essentially complete (99.63%) and free from contamination. The genome has a G+C content of 37.3% and is predicted to contain 2,929 protein-coding genes and 60 structural RNAs. Analysis of *E. faecalis* phylogeny using the GTDB revealed that *E. faecalis* AHG0090 clusters closely with three strains termed *E. faecalis* TX0630, TX0635 and TX0645, and distally from the *E. faecalis* type strains (*E. faecalis* ATCC19433 and 29200), and other gut commensal (e.g., *E. faecalis* PC1.1, 62 and Symbioflor1) and pathogenic (*E. faecalis* V583) strains (Figure [6](#F6){ref-type="fig"}A). Although *E. faecalis* is characterized by extensive horizontal gene transfer there is a high degree of synteny between *E. faecalis* AHG0090 and the closed commensal (*E. faecalis* 62) and pathogenic (*E. faecalis* V583) strains (Figure [6](#F6){ref-type="fig"}B).

![**(A)** GTDB-based phylogeny of *Enterococcus faecalis* as determined from the concatenation of 120 universal bacterial-specific marker genes. The source of individual commensal (green), uncharacterized (orange) and pathogenic (red) strains is indicated. The bootstrap values are indicated using a cut-off of \>80 or \>90%. **(B)** The extent of genome synteny between *E. faecalis* AHG0090 and a representative pathogenic strain (*E. faecalis* V583) and commensal (*E. faecalis* 62) that have closed genome sequences. The red lines for *E. faecalis* V583 and 62 indicated boundaries of the chromosomes and plasmids whereas the red lines for *E. faecalis* AHG0090 indicate individual contig sequences.](fimmu-09-00790-g006){#F6}

We identified several plasmids in the *E. faecalis* AHG0090 genome sequence. pAHG0090c is a predicted to be 76,529 bp and is comprised of 11 contigs. It is predicted to encode 80 genes and displays sequence similarity and synteny to another plasmid from *E. faecalis* NKH15 \[pMG2200 (106,527 bp), 99% identity and 72% coverage\]. Enterococcal plasmids are widely shared through horizontal transfer, and we identified an aggregation substance encoding regulon that mediates efficient contact between donor and recipient bacteria to facilitate plasmid transfer ([@B38]) and adhesion to host cells ([@B39], [@B40]). We also identified two closed endogenous plasmid sequences in the genome sequence data. pAHG0090b is a 5,121 bp plasmid that exhibits sequence similarity to plasmids from *E. faecalis* 62 \[EF62pA (5,143 bp), 99% identity and 100% coverage\] ([@B41]) and *E. faecalis* S-86 \[pS86 (5,149 bp), 99% identity and 99% coverage\] ([@B42]). pAHG0090b has a G+C content of 37% and is predicted to encode 6 proteins. pAHG0090a is a 1,925 bp plasmid that exhibits extensive sequence similarity to a cryptic plasmid of similar size from *Enterococcus faecium* 226 \[pMBB1 (1,932 bp), 96% identity and 67% coverage\] ([@B43]), and larger cryptic plasmids from *Lactococcus fermentum* KC5b \[pKC5b (4,392 bp), 99% identity and 75% coverge\] ([@B44]) and *Lactococcus lactis* \[pCRL291.1 (4,640 bp), 89% identity and 70% coverage\]. pAHG0090a has a G+C content of 33% and is predicted to encode a single protein predicted to function in plasmid replication.

We also identified pEHR513112 in the genome sequence. There were four differences between the compiled pEHR513112 sequence and the vector carried by *E. faecalis* AHG0090. We identified a G86T transversion in the *cphy_3290* promoter and a C2407T transition in *oriT* vector modules. We also identified a 1 bp deletion at the 5′ (AscI) end and a separate 11 bp deletion at the 3′ (PmeI) end of the pMB1 module. Notably, these deletions occurred within the primer sequences used to PCR amplify the pMB1 module.

The *E. faecalis* AHG0090 chromosome is predicted to encode a range of niche factors that likely support colonization and persistence in the infant gut. Many enterococci are non-motile and the ability to adhere to the host epithelium likely plays a role in preventing washout. We identified an Ebp-like pilus, the microbial surface component recognizing adhesive matrix molecules protein Ace and several adhesins including EfbA that mediate adhesion to host structural factors (e.g., collagen, fibrinogen, and laminin) and support biofilm formation ([@B45]--[@B47]). *E. faecalis* AHG0090 also encodes several proteins that enable foraging of host glycans ([@B48], [@B49]) and it also encodes both the GelE and SprE proteases that have been proposed to support the nutrient requirements of the bacterium by digesting host proteins and cells ([@B50]). We also identified several proteins that likely modulate interactions with the host immune system including an internalin like protein that may support intracellular persistence ([@B51]) and a capsule that may contribute to immune evasion ([@B52]). Notably, we also identified a TIR domain protein previously shown to suppress MyD88 signaling and NF-κB activation by *E. faecalis* V583 ([@B13]). As expected, *E. faecalis* AHG0090 does not encode Mam like sequences and we did not identify any candidate genes and/or regulons likely to encode a low molecular weight NF-κB suppressive peptidic bioactive \[e.g., bacteriocin CBT-SL5 ([@B53]), the *E. faecalis* SL-5 bacteriocin CBT-SL5 is likely same as bacteriocin ESL5 which is produced by the same strain ([@B54])\] such as the bioactive we describe.

Discussion {#S4}
==========

The early microbial colonizers of the gut help establish a homeostatic relationship between the host and its microbiota ([@B4], [@B55]). *E. faecalis* comprises part of the vaginal ([@B12], [@B56]) and breastmilk ([@B57]--[@B59]) microbiota, and is widely shared between mothers and their infants. It is increasingly recognized that early life events (e.g., method of birth, feeding) modify risks for several chronic diseases ([@B60], [@B61]) and this may be related at least in part to early differences in gut colonization and immune modulation. Much remains to be discovered about the bacteria and bioactive factors that underpin these events, and whether they could be exploited to optimize health and appropriate establishment of gut mucosal immunity.

In this study, we describe the isolation of a genetically tractable *E. faecalis* strain from infant stool and demonstrate that it produces a potent NF-κB suppressive bioactive. The suppressive activity of *E. faecalis* AHG0090 was clearly apparent in early EX phase culture supernatants and did not increase significantly from MX phase onward. This suggests the bioactive is produced in early growth and persists in the culture supernatant through the proceeding phases of growth. The closely related bacterium *L. plantarum* WCFS1 also exerts NF-κB and IFNγ suppressive effects and produces bioactives in a growth phase-dependent manner ([@B37], [@B62]), possibly as a response of the bacterium to increased nutrient limitation during the transition from mid-log to stationary phase. We determined that the ability of *E. faecalis* AHG0090 to suppress NF-κB in our reporter cell lines was comparable to that of *F. prausnitzii* A2-165. *F. prausnitzii* is widely regarded as a model anti-inflammatory fastidious gut bacterium and produces a 15 kDa protein termed Mam that underpins NF-κB suppression ([@B16], [@B17]). Mam-derived peptides are detectable in *F. prausnitzii* culture supernatants, however, it has not yet been reported whether the NF-κB suppressive activity is mediated by Mam and/or its peptide derivatives. While this remains to be further explored, we showed that NF-κB activation was suppressed by the \<3 kDa culture supernatant fraction, and the suppressive effect was abrogated by heat or proteinase K treatment. Taken together, this suggests suppression of NF-κB by *F. prausnitzii* in our assays was mediated by \<3 kDa Mam-derived peptides. Our data also suggests the NF-κB suppressive activity of *E. faecalis* AHG0090 is mediated by a low molecular weight peptidic bioactive although it is more resilient to heat and proteinase K treatment than Mam-derived peptides.

The *E. faecalis* AHG0090 genome sequence allowed us to readily predict "known" functionalities. Both commensal and pathogenic strains of *E. faecalis* have previously been shown to produce NF-κB suppressive factors ([@B12], [@B13]). *E. faecalis* V583 encodes a TIR domain containing protein, TcpF, that suppresses NF-κB by interfering with MyD88 signaling ([@B13]). NF-κB suppression by TcpF is dependent on contact between the bacterium and host cells and this protein is also encoded by *E. faecalis* AHG0090 and other non-pathogenic isolates \[e.g., *E. faecalis* PC1.1 ([@B63]), *E. faecalis* 62 ([@B41])\]. Separately, the human vaginal isolate *E. faecalis* MN1 produces an NF-κB suppressive tetramic acid termed reutericyclin ([@B12]). The reutericyclin regulon has been described in *L. reuteri* and includes a non-ribosomal peptide synthetase (NRPS) and polyketide synthetase (PKS) enzymes that function in its biosynthesis ([@B64]). *E. faecalis* AHG0090 does not encode the reutericyclin regulon and nor does it encode any NRPS or PKS genes. We did not identify any Mam like sequences which is consistent with its narrow phylogenetic distribution ([@B16]) nor did we identify any genes that might encode the candidate \<3 kDa peptidic bioactive. It is increasingly facile to produce microbial genomic sequence data but the ability to link genes with function remains challenging. It is estimated that the human gut microbiome is comprised of as much as 9.8 million non-redundant genes ([@B65]). However, despite the wealth of microbial (meta)genomic data that is now publicly available the vast majority of genes remain functionally uncharacterized ([@B66], [@B67]). For instance, it is widely acknowledged the gut microbiota exerts a broad range of immunomodulatory activities \[e.g., see Ref. ([@B68])\], however, with some notable exceptions ([@B16], [@B69]), the genes underpinning these capacities remain largely cryptic.

Microbial culturing is a time consuming and labor-intensive process although this provides the best opportunity to link genes with function. We believe focusing culturing efforts on genetically tractable strains will ultimately expedite the functional dissection of the microbiome. We previously observed the pEHR plasmids are stably maintained in their recipient hosts ([@B15]). We have now demonstrated that they are maintained in *E. faecalis* AHG0090 and that this strain can be manipulated using standard molecular microbiology approaches for transformation and plasmid curing. We did identify some minor differences between the compiled pEHR vector sequences and those produced from the genome sequence data and we believe that these likely occurred during the vector construction process. We are continuing to extend the functionalities of the pEHR vector system and we anticipate that this will enable us to apply forward and/or reverse genetic approaches to functionally dissect *E. faecalis* AHG0090 and other gut microbes. For instance, NF-κB is a master regulator of inflammation and gut barrier integrity, and is central to the pathogenesis of several chronic (gut) diseases ([@B70]--[@B72]). The gut microbiota produces a plethora of immunomodulatory bioactives and these could be used as lead molecules to catalyze the development of new biotechnologies and therapeutics. Genetic methods offer new opportunities to identify these bioactives and they complement existing -omic-based methods for gene and protein function discovery ([@B73], [@B74]).

In conclusion, we demonstrated that MPM can be used to isolate genetically tractable bacteria from the human gut that possess potent anti-inflammatory activities. Although *E. faecalis* is among the best characterized *Firmicutes* affiliated gut bacteria our data suggests this taxon possesses novel anti-inflammatory capacities. Several fastidious anaerobic gut bacteria have been suggested as next generation probiotics for chronic gut diseases but *E. faecalis* may be a superior candidate due to its ease of propagation. We anticipate the genetic dissection of *E. faecalis* AHG0090 will provide new insights into the immunomodulatory capacity of this taxon, and a deeper understanding of the early life events that help establish a tolerogenic immune response.
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